10 presentations were found matching your search word IS-W1 .

International Session (Workshop)1 (JSGE, JSH)

November 4, 15:00–17:00, Room 11 (Portopia Hotel South Wing Topaz)

New developments in drug discovery research and treatment for hepatitis B

Time Slot for Each Speaker: (Time slots vary depending on presentations. Please prepare your presentation as below.)
  IS-W1-1_H，IS-W1-5_G，IS-W1-8_G : 10 min. for oral presentation, 2 min. for Q&A
  Other Presentations: 8 min. for oral presentation, 2 min. for Q&A
Discussion: Not to be held
Introductory Meeting: Not to be held
  • Chairperson:
    Tatsuya KantoThe Research Center for Hepatitis and Immunology, National Center for Global Health and Medicine
  • Chairperson:
    Yasuhito TanakaDepartment of Gastroenterology and Hepatology, Faculty of Life Sciences, Kumamoto University
  • Discussant:
    Kenichi MorikawaDepartment of Gastroenterology and Hepatology, Hokkaido University
  • Discussant:
    Sachiyo YoshioDepartment of Liver Disease, The Research Center for Hepatitis and Immunology, National Center for Global Health and Medicine

IS-W1-1_H
Enhancing functional cure in patients with chronic hepatitis B infection

Lung-Yi Mak The University of Hong Kong

IS-W1-2_H
DOCK11 might be a candidate druggable target for HBV cure

Ying-Yi Li Department of Gastroenterology, Kanazawa University Graduate School of Medicine

IS-W1-3_G
Identification of an Interferon-Inducible Regulatory Molecule, IFI44L, for Hepatitis B Virus cccDNA in Primary Human Hepatocytes

Takuto Nosaka Second Department of Internal Medicine, Faculty of Medical Sciences, University of Fukui

IS-W1-4_H
Novel anti-HBV combination treatment of CRISPR/Cas9 and suppression of NHEJ-mediated DNA repair Young Award

Kazuhiro Murai Department of Gastroenterology and Hepatology, Osaka University, Graduate School of Medicine

IS-W1-5_G
CRISPR-mediated genome editing for HBV Cure: the promise and challenge

Hung-Chih Yang National Taiwan University College of Medicine

IS-W1-6_H
Exosome-associated tetraspanin CD63 is a potential target for the inhibition of infectious envelope formation of hepatitis B virus

Jun Inoue Department of Gastroenterology, Tohoku University Hospital

IS-W1-7_G
SA-5, A novel oral agonist of Toll-like Receptor (TLR) 7, induces HBs antigen specific immune reaction in chronic HBV infection model mice

Takayasu Ideta Department of Laboratory Medicine, Gifu University Graduate School of Medicine

IS-W1-8_G
Impact of HBsAg on virus-specific T cells in chronic HBV infection

Nina Le Bert Duke-NUS Medical School

IS-W1-9_H
OX40 stimulation of HBV-specific CD8+ T cells achieves long-term HBs suppression.

Masanori Isogawa Research Center for Drug and Vaccine Development, National Institute of Infectious Diseases

IS-W1-10_G
HBsAg reduction was evident in 30 months follow-up after administration with therapeutic vaccine containing HBs/HBc antigen in chronic HBV carriers

Osamu Yoshida Department of Gastroenterology and Metabology, Ehime University Graduate School of Medicine

Page Top

Page Top